Zenlabs EthicaBOM:530697 +0.93%53 ROE % is 0.05% as of Mar. 2026, which is 99% below its 10-year median of 6.94. GuruFocus rates BOM:530697 with a GF Score™ of 53/100 and a GF Value™ of ₹29.34 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 113 Medical Distribution companies, Zenlabs Ethica ranks worse than 89.38% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Zenlabs Ethica's annualized net income for the quarter that ended in Mar. 2026 was ₹0.0 Mil. Zenlabs Ethica's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹85.1 Mil. Therefore, Zenlabs Ethica's annualized ROE % for the quarter that ended in Mar. 2026 was 0.05%.
The historical rank and industry rank for Zenlabs Ethica's ROE % or its related term are showing as below:
BOM:530697'
s ROE % Range Over the Past 10 Years
Min: -20.44 Med: 6.94 Max: 18.18
Current: -19.69
During the past 13 years, Zenlabs Ethica's highest ROE % was 18.18%. The lowest was -20.44%. And the median was 6.94%.
BOM:530697's ROE % is ranked worse than 89.38% of 113
companies
in the Medical Distribution industry
Industry Median: 7.1
vs BOM:530697: -19.69
Zenlabs Ethica (BOM:530697) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Zenlabs Ethica ROE % Related Terms
Zenlabs Ethica ROE % Historical Data
* Premium members only.
The historical data trend for Zenlabs Ethica's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Zenlabs Ethica's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenlabs Ethica ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Zenlabs Ethica's ROE % distribution charts can be found below:
* The bar in red indicates where Zenlabs Ethica's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Zenlabs Ethica (BOM:530697) has a ROE % of 0.05% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Zenlabs Ethica and its competitors. This is 99% below median its historical median of 6.94. According to the industry distribution chart, Zenlabs Ethica ranks #101 out of 113 companies in the Medical Distribution industry, placing it in the top 89.4%.
Is Zenlabs Ethica's ROE % too high?
Zenlabs Ethica's current ROE % of 0.05% is 99% below median its 10-year median of 6.94. The Medical Distribution industry median ROE % is 7.10. Zenlabs Ethica's value of 0.05% is 99.3% below this industry median. Based on the distribution chart, Zenlabs Ethica ranks #101 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Zenlabs Ethica has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zenlabs Ethica's ROE % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Zenlabs Ethica ranks #101 out of 113 companies for ROE %. This places Zenlabs Ethica in the lower half of its industry. The industry median ROE % is 7.10. Zenlabs Ethica's value of 0.05% is 99.3% below this benchmark. While the company's 10-year median is 6.94 vs. the industry median of 7.10, Zenlabs Ethica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenlabs Ethica's current ROE % of 0.05% is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Zenlabs Ethica and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenlabs Ethica's current ROE % is 0.05%, which is 99% below median its own 10-year median of 6.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenlabs Ethica stock overvalued right now?
Based on GuruFocus' analysis, Zenlabs Ethica (BOM:530697) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹29.34, compared to a current price of ₹35.80 — trading 22% above its estimated fair value. The current ROE % is 0.05%, which is 99% below median its 10-year median of 6.94 and 99.3% below the Medical Distribution industry median of 7.10. Zenlabs Ethica's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Zenlabs Ethica (BOM:530697), the current ROE % is 0.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenlabs Ethica (BOM:530697) Overvalued in 2026?
Based on GuruFocus' analysis, Zenlabs Ethica stock appears to be overvalued.
The current stock price of ₹35.80 is trading 22% above its estimated GF Value™ of ₹29.34.
GuruFocus considers Zenlabs Ethica to be Modestly Overvalued.
Key valuation signals for BOM:530697:
ROE %: 0.05% (99% below median its 10-year median of 6.94)
GF Value™: ₹29.34 vs. price of ₹35.80 (22% above fair value)
Industry Position: 99.3% below the Medical Distribution median (#101 of 113)
No single metric tells the full story. See the BOM:530697 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.
53GF Score
Get the complete analysis for BOM:530697
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530697 has been successfully added to your 
